RWD277 COST-UTILITY IN DAPAGLIFLOZIN VERSUS SACUBITRIL-VALSARTAN THERAPY IN HEART FAILURE WITH REDUCED EJECTION FRACTION [DESTINY-HF]: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL-BASED ECONOMIC EVALUATION
Abstract
Authors
Muhammad Aaqib Shamim Shoban Babu Varthya Atul Kaushik Sneha Ambwani Pradeep Dwivedi Surjit Singh Rahul Choudhary Surender Deora Krishna Tiwari